Serotonin syndrome after challenge with the 5-HT agonist meta- chlorophenylpiperazine

Psychiatry Research

Volumn 79, Issue 3, 1998, Pages 207-212

  Klaassen, Tineke ^a   Ho Pian, Kamini L ^b   Westenberg, Herman G M ^b   Den Boer, Johan A ^b   Van Praag, Herman M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Case report; Human; mCPP; Plasma; Serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; BROMAZEPAM; CLOMIPRAMINE; DIAZEPAM; FLUVOXAMINE; RITANSERIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DIAPHORESIS; DRUG EFFECT; DRUG RECEPTOR BINDING; DYSTHYMIA; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; MALE; MYOCLONUS; NAUSEA; OBSESSION; PRIORITY JOURNAL; SEROTONIN BLOOD LEVEL; SEROTONIN SYNDROME; SOCIAL PHOBIA; VERTIGO;

ADULT; AKATHISIA, DRUG-INDUCED; AUTONOMIC NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCLONUS; PIPERAZINES; SEROTONIN AGONISTS; SYNDROME;

EID: 0345164362     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(98)00044-4     Document Type: Article

References (33)

1. Asnis G.M., Harkavy Friedman J.M., Iqbal N., Bajwa W.K., Kalus O., Rubinson E., Grosz D., van Praag H.M., Cooper T.B. The drug-free period: a methodological issue (comment). Biological Psychiatry. 27:1990;657-660.
2. Benkelfat C., Murphy D.L., Hill J.L., George D.T., Nutt D., Linnoila M. Ethanol-like properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Archives of General Psychiatry. 48:1991;383.
3. Bodner R.A., Lynch T., Lewis L., Kahn D. Serotonin syndrome. Neurology. 45:1995;219-222.
4. Brennan D., Mac Manus M., Howe J., McLoughlin J. 'Neuroleptic malignant syndrome' without neuroleptics (letter). British Journal of Psychiatry. 152:1988;578-579.
5. Brewerton T.D., Mueller E.A., Lesem M.D., Brandt H.A., Quearry B., George T., Murphy D.L., Jimerson D.C. Neuroendocrine responses to m-chlorophenylpiperazine and l-tryptophan in bulimia. Archives of General Psychiatry. 49:1992;852-861.
6. 1c) receptors. Journal of Pharmacology and Experimental Therapeutics. 2142:1987;552-557.
7. Garvey M.J., Tuason V.B., Johnson R.A., Valentine R.H., Cooper T.B. Elevated plasma tricyclic levels with therapeutic doses of imipramine. American Journal of Psychiatry. 141:1984;853-856.
8. Goldberg R.J. Serotonin syndrome from trazodone and buspirone (letter). Psychosomatics. 33:1992;235.
9. Guze B.H., Baxter L.R. Jr. The serotonin syndrome; case responsive to propranolol (letter). Journal of Clinical Psychopharmacology. 6:1986;119-120.
10. Hamik A., Peroutka S.J. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biological Psychiatry. 5:1989;569-575.
11. Hommer D., Andreason P., Rio D., Williams W., Ruttimann U., Momenan R., Zametkin A., Rawlings R., Linnoila M. Effects of m-chlorophenylpiperazine on regional brain glucose utilisation: a position emission tomographic comparison of alcoholic and control subjects. Journal of Neuroscience. 17(8):1997;2796-2806.
12. Joseph-Vanderpool J.R., Jacobsen F.M., Murphy D.L., Hill J.L., Rosenthal N.E. Seasonal variation in behavioral responses to m-CPP in patients with seasonal affective disorder and controls. Biological Psychiatry. 33:1993;496-504.
13. Kahn R.S., Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biological Psychiatry. 30:1991;1139-1166.
14. Kahn R.S., Wetzler S., Asnis G.M., Kling M.A., Suckow R.F., van Praag H.M. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology. 100:1990;339-344.
15. Kahn R.S., Kalus O., Wetzler S., Cahn W., Asnis G.M., van Praag H.M. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Psychiatry Research. 33:1990;189-198.
16. Kline S.S., Maruo L.S., Scala-Barnett D.M., Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clinical Pharmacology. 8:1989;510-514.
17. Krystal J.H., Webb E., Cooney N., Kranzler H.R., Charney D.S. Specificity of ethanol like effects elicited by serotonergic and noradrenergic mechanisms. Archives of General Psychiatry. 51:1994;898-911.
18. Lejoyeux M., Rouillon F., Adès J. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine. Acta Psychiatrica Scandinavica. 88:1993;369-371.
19. Lejoyeux M., Ades J., Rouillon F. Serotonin syndrome - incidence, symptoms and treatment. CNS Drugs. 2:1994;132-143.
20. McNair, D.M., Lorr, M., Droppelman, L.F., 1988. Manual for the Profile of Mood States. Educational and Industrial Testing Service, San Diego, California.
21. Neuvonen P.J., Pohjola-Sintonen S., Tacke U., Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 342(II):1993;1419.
22. Reeves R.R., Bullen J.A. Serotonin syndrome produced by paroxetine and low-dose trazodone (letter). Psychosomatics. 36(2):1995;159.
23. 3 receptors. Life Sciences. 50:1992;599-605.
24. Roy A., Virkkunen M., Linnoila M. Reduced central serotonin turnover in a subgroup of alcoholics? Progress in Neuropsychopharmacology and Biological Psychiatry. 11:1987;173-177.
25. Sandyk R. L-Dopa induced 'serotonin syndrome' in a parkinsonian patient on bromocriptine (letter). Journal of Clinical Psychopharmacology. 6:1986;194-195.
26. 1b receptor ligands exist? Archives of Pharmacology. 339:1989;675-683.
27. Sevy S., Brown S.L., Wetzler S., Kotler M., Molcho A., Plutchik R., van Praag H.M. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiatry Research. 53:1994;219-223.
28. 2 receptors in interneurons. Synapse. 9:1991;208-218.
29. Smith L.M., Peroutka S.J. Differential effects of 5-hydroxytryptamine 1a selective drugs on the 5-HT behavioral syndrome. Pharmacology, Biochemistry and Behavior. 24:1986;1513-1519.
30. Sternbach H. The serotonin syndrome (see comments). American Journal of Psychiatry. 148:1991;705-713.
31. Stein D.J., Hollander E., DeCaria C.M., Simeon D., Cohen L., Aronowitz B. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response and clinical measures. Biological Psychiatry. 40:1996;508-513.
32. Yamada J., Sugimoto Y., Horisaka K. The evidence for the involvement of the 5-HT1A receptor in the 5-HT syndrome induced in mice by tryptamine. Japanese Journal of Pharmacology. 51:1989;421-424.
33. Zacchia C., Pihl R.O., Young S., Ervin F. The influence of altered tryptophan availability on ethanol intoxication in normal men. Journal of Studies on Alcohol. 48:1987;535-540.